GLP-1 that increases insulin secretion when blood sugar is high, slows gastric emptying to promote a feeling of fullness, and reduces appetite and cravings.

Tirzepatide mimics the effects of two natural hormones—GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide)—which work together to: boost insulin secretion when blood glucose is high, slow gastric emptying to increase satiety, reduce appetite and food intake, improve insulin sensitivity and glucose regulation.

A promising new investigational medication designed to address obesity and type 2 diabetes by targeting multiple metabolic pathways. It is a next-generation, multi-receptor agonist that activates GLP-1, GIP, and glucagon receptors, potentially offering enhanced effects on weight loss and blood sugar regulation compared to earlier therapies.

Works with GLP-1’s or alone for increased appetite suppression.